Optimi Health secures naturally derived ibogaine to expand its psychedelic drug portfolio

Optimi Health Corp. (OPTH) — Optimi Health announced it had secured naturally derived ibogaine, in both hydrochloride and freebase forms, from two sources, with development of a finished drug product expected to begin in summer at its GMP facility in British Columbia.

The move positions Optimi to supply ibogaine as U.S. federal and Texas-led interest in ibogaine research grows. It extends the company's portfolio beyond psilocybin and MDMA into one of 2026's most closely watched psychedelic compounds.

Source: sec.gov

For the rest of that week's sector news, read our week in review.